03719nam a2200337   4500001000800000007000300008008004100011040000800052041000800060100004100068245007100109300002300180520258400203650003302787650003802820650003802858650003202896700003002928700002702958700003202985700003003017700003303047700003003080700003203110700002403142700003003166700002703196773011003223942003103333999001703364ESSALUDta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aHeerspink, Hiddo J. L.eAutor954043  aFinerenone in persons with chronic kidney disease without diabetes  apáginas: 533-545  aBackground: In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD). Whether finerenone has similar effects in patients without diabetes who have CKD is unknown. Methods: We randomly assigned adults without diabetes who had CKD (estimated glomerular filtration rate [eGFR], 25 to <90 ml per minute per 1.73 m2 of body-surface area) and albuminuria (urinary albumin-to-creatinine ratio, 200 to ≤3500, with albumin in milligrams and creatinine in grams) and were using a renin–angiotensin system inhibitor to receive finerenone (10 or 20 mg daily) or placebo. The primary outcome was the total eGFR slope (mean annual rate of change in the eGFR from baseline to month 32), assessed with a two-slope linear spline mixed-effects model. Secondary outcomes included a composite of kidney or cardiovascular events (reduction from baseline of at least 57% in the eGFR, kidney failure, hospitalization for heart failure, or death from cardiovascular causes), a composite of the two kidney events, and a composite of the two cardiovascular events. Results: A total of 1584 participants underwent randomization — 793 were assigned to the finerenone group, and 791 to the placebo group. The mean (±SD) baseline eGFR was 46.8±16.2 ml per minute per 1.73 m2 with finerenone and 46.6±16.0 ml per minute per 1.73 m2 with placebo. The mean annual rate of change in the eGFR from baseline to month 32 was −3.3 ml per minute per 1.73 m2 (95% confidence interval [CI], −3.6 to −3.1) with finerenone and −4.0 ml per minute per 1.73 m2 (95% CI, −4.3 to −3.8) with placebo (difference, 0.7; 95% CI, 0.3 to 1.1; P<0.001). Prespecified hierarchical testing showed that the risk of a composite kidney or cardiovascular outcome event was lower with finerenone than with placebo (hazard ratio, 0.77; 95% CI, 0.60 to 0.99; P=0.04); the hazard ratio was 0.78 (95% CI, 0.60 to 1.01) for the composite of the two kidney events and 0.60 (95% CI, 0.27 to 1.33) for the composite of the two cardiovascular events. The most common adverse event was hyperkalemia (135 participants [17.0%] with finerenone and 105 [13.3%] with placebo); hyperkalemia events led to discontinuation of the trial regimen in 12 participants (1.5%) and 1 participant (0.1%), respectively, and to hospitalization in 7 (0.9%) and 5 (0.6%). Conclusions: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months.  aCARDIOLOGÍA GENERAL953638  aENFERMEDAD RENAL CRÓNICA932213  aMEDICINA CLÍNICA GENERAL953666  aNEFROLOGÍA GENERAL953655  aNeuen, Brendon L. 954044  aAgarwal, Rajiv 954045  aCherney, David Z.I. 954046  aLam, Carolyn S.P. 954047  aTuttle, Katherine R. 954048  aWanner, Christoph 945757  aSarafidis, Pantelis 954049  aJongs, Niels954050  aSmeijer, J. David 954051  aBrinker, Meike 9540520 022717922644dMassachusetts NEJM GroupoNEJM009tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-14zSQB  c22812d22812